111 Inc

111 Inc(YI)股票分析

$2.900

-0.078 (-2.68%)收盘时

Loading chart…
最高
2.950
开盘
2.950
成交量加权均价
2.92
成交量
56.91K
市值
92.95M
最低
2.900
成交额
165.98K
企业价值/息税折旧摊销前利润(TTM)
0.08

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.

AI 分析 of 111 Inc (YI)

持有

Currently, 111 Inc (YI) is not a strong buy due to its significant financial challenges. The stock is trading at $2.90, with a 52-week high of $11.17, indicating a potential for recovery, but the RSI is at 36.67, suggesting it is nearing oversold territory. However, the company reported a 33.1% year-over-year revenue decline in Q1 2026 and a net income of -$37.04 million in Q1 2026, which raises concerns about its profitability and future growth prospects. The main risk is the company's high debt-to-equity ratio of 1199.60%, indicating significant financial leverage and potential liquidity issues.

分析师评级(1)

买入
1 买入
0 持有
0 卖出
当前: 2.90
最低
—
平均
—
最高
—

估值指标

111 Inc(YI)当前预期市盈率为 0.00,5 年平均预期市盈率为 18.30。

预期市盈率

合理
5 年均值 P/E
18.30
当前P/E
0.00
高估
68.20
低估
-31.60

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
3.81
当前EV/EBITDA
0.08
高估
27.87
低估
-20.26

预期市销率

严重低估
5 年均值 P/S
0.07
当前P/S
0.00
高估
0.09
低估
0.04

事件时间线

2026-09-28 (ET)

06:30:00

111, Inc. Establishes Special Committee to Evaluate Strategic Proposals

2026-09-17 (ET)

05:30:00

111 Inc. Receives Acquisition Proposal at $0.226 per Share

2026-01-30 (ET)

14:50:00

111 Inc ADR Trading Halted Due to Volatility Trading Pause

2025-02-11 (ET)

07:01:56

111, Inc. regains Nasdaq compliance

2025-01-08 (ET)

04:08:32

111, Inc. announces one-for-twenty ADS ratio change

资讯

YI 常见问题 —— 由 Alphio AI 解答

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market. It operates in the Healthcare sector (DRUG STORES AND PROPRIETARY STORES industry).

Currently, 111 Inc (YI) is not a strong buy due to its significant financial challenges. The stock is trading at $2.90, with a 52-week high of $11.17, indicating a potential for recovery, but the RSI is at 36.67, suggesting it is nearing oversold territory. However, the company reported a 33.1% year-over-year revenue decline in Q1 2026 and a net income of -$37.04 million in Q1 2026, which raises concerns about its profitability and future growth prospects. The main risk is the company's high debt-to-equity ratio of 1199.60%, indicating significant financial leverage and potential liquidity issues.

1 analysts cover YI: 1 rate it Buy, 0 Hold and 0 Sell.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易